 |
 |
Wait a minute...recruitment is currently under way for a Ceregene clinical trial to be conducted at a number of sites. From Movement Disorder News, the newsletter of the Beth Israel Parkinson's Disease and Movement Disorders Research Center (Fall 2010, Issue No. 2): "...CERE-120 has been shown to be safe in animals and in people with PT, and it has been shown to protect and improve the function of damaged brain cells. CERE-120 has the potential to improve PD symptoms and possibly slow disease progression." There is nothing about this that says "failure" to me. And about the so-called failure of GDNF: well... Kathleen Clinical Drug Trials: Growth Factor and Parkinson's Disease On 27 October 2010 13:51, mschild <[log in to unmask]> wrote: > NEURTURIN FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE > > Lancet Neurology [2010] Oct 20 [Epub ahead of print] (Marks WJ Jr, Bartus > RT, > Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, > Verhagen > L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman > R, > Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, > Kordower JH, Olanow CW.) Complete abstract > > Neurturin was hailed by its sponsors Ceregene and the Michael J Fox > Foundation > as having great potential in the treatment of Parkinson's Disease, but has > been found to be completely ineffective. Neurturin (CERE-120) is an > experimental drug that contains the human gene for a growth factor called > neurturin. It is used to deliver the neurturin gene by surgical means, > directly into the brain of people with Parkinson's Disease. It was found to > be > worse than doing nothing, as it was as ineffective as sham surgery (doing > nothing) yet still caused severe adverse events in a third of the patients. > Neurturin is the same type of treatment as GDNF reference. GDNF was also > previously hailed as a great breakthrough in the treatment of Parkinson's > Disease. Yet all major clinical trials of GDNF and Neurturin have failed. > > > www.viartis.net > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn